COVID-19 Response Efforts - April 14, 2020

The State of Ohio Board of Pharmacy is committed to protecting the health and safety of Ohioans during the COVID-19 outbreak. The Board posted a document on its website that provides COVID-19 guidance and response efforts, including the issuance of waivers to assist licensees in addressing operational needs. This document will be updated regularly and can be accessed by visiting: www.pharmacy.ohio.gov/COVID. Please be advised that new and updated waivers were issued today (see below).

For more information on the state’s efforts to address coronavirus, visit www.coronavirus.ohio.gov or call 1-833-4-ASK-ODH.

New and Updated Waivers and Guidance Issued

- **UPDATED:** Authorized prescribers to delegate personally furnishing non-controlled drugs to nurses licensed in accordance with Chapter 4723. of the Revised Code. This expanded resolution incorporates language from a previous resolution issued on 3/18/2020 that authorized prescribers to delegate personally furnishing non-controlled drug samples to nurses licensed in accordance with Chapter 4723. of the Revised Code. This new resolution authorizes prescribers to delegate personally furnishing of all non-controlled drugs as opposed to drug samples. This updated guidance can be accessed here.

- **UPDATED:** Authorized licensees conducting sterile compounding to reuse certain personal protective equipment (PPE). The waiver was updated to align with recently released PPE conservation guidance issued by the FDA. This updated guidance can be accessed here.

- **NEW:** Authorized the sale and shipment of patient-specific, non-reportable dangerous drugs by non-Ohio licensed border state facilities to patients residing in the state under certain conditions. This guidance can be accessed here.

- **NEW:** Authorized an Ohio pharmacy to request a temporary waiver to permit a pharmacist to supervise up to five pharmacy technician trainees at one time (up from the current limit of three). This guidance can be accessed here.

Emergency Rules for Dispensing Chloroquine and Hydroxychloroquine

**UPDATED 4/14/2020**

On March 22, 2020, Governor Mike DeWine authorized the State of Ohio Board of Pharmacy to file emergency rule 4729-5-30.2 of the Administrative Code that places limits on dispensing chloroquine and hydroxychloroquine.

**IMPORTANT REMINDER:** The rule only applies to prescriptions that are dispensed for outpatient use.

On April 14, 2020, the Board’s Executive Director, in consultation with the Board President, authorized or updated the following as it relates to the dispensing of chloroquine and hydroxychloroquine for presumptive positive COVID-19 patients:

- For the continuation of inpatient treatment for COVID-19 using chloroquine or hydroxychloroquine for patients discharged from a hospital. The prescriber shall be required to notate on the prescription that the patient has been discharged from the hospital and the prescription shall be for no more than a seven-day supply (no refills authorized). *(Originally Authorized 3/26/2020, Updated 4/14/2020)*

- For patients discharged from an emergency department, for a probable COVID-19 diagnosis based upon case classifications established by the Ohio Department of Health. The prescriber shall be required to notate on the prescription that the patient has been discharged from the emergency department and the prescription shall be for no more than a seven-day supply (no refills authorized). *(Originally Authorized 3/26/2020, Updated 4/14/2020)*
emergency department with a probable COVID-19 diagnosis and the prescription shall be for no more than a seven-day supply (no refills authorized). (Authorized 4/14/2020)

To assist licensees in complying with this rule, the Board has developed the following frequently asked questions document, which was also recently updated: www.pharmacy.ohio.gov/COVIDRx

**DEA Issues Additional Guidance for Emergency Temporary Sites**

The DEA has issued additional guidance for emergency temporary sites, which can be accessed by visiting: https://www.deadiversion.usdoj.gov/coronavirus.html

Licensees that are registering temporary sites with the Board of Pharmacy and the DEA for the use of controlled substances are expected to comply with this guidance.